Les Laboratoires Servier has filed a patent for a pharmaceutical composition combining palbociclib tosylate and letrozole in one dosage unit. The invention includes a unique blister packaging for a specific dosage regimen. GlobalData’s report on Les Laboratoires Servier gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Les Laboratoires Servier, Cancer treatment biomarkers was a key innovation area identified from patents. Les Laboratoires Servier's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Combination pharmaceutical composition of palbociclib tosylate and letrozole
A recently filed patent (Publication Number: US20230364093A1) outlines a method for the treatment of cancer, specifically breast cancer, that is locally advanced or metastatic and involves cancer cells with hormone receptors but not producing abnormally large amounts of the HER2 receptor. The method includes administering a pharmaceutical composition containing the 4-toluenesulfonic acid salt of palbociclib and letrozole to the patient. The treatment regimen may involve alternating administration with letrozole and specific dosing schedules to optimize efficacy.
Furthermore, the patent also covers a method for the treatment of HR-positive, HER-negative breast cancer using the same pharmaceutical composition. The treatment involves administering the 4-toluenesulfonic acid salt of palbociclib and letrozole, with the option of periodically replacing or supplementing with letrozole alone. The dosing regimen includes specific time frames for administration to ensure the effectiveness of the treatment. The patent also details the characteristics of the pharmaceutical composition, including the salt form of palbociclib and letrozole, as well as the form of granules for administration. Overall, the patent provides a comprehensive method for treating specific types of cancer using a novel pharmaceutical composition.
To know more about GlobalData’s detailed insights on Les Laboratoires Servier, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
